Pfizer and Astellas Report Follow-up Data from P-III (KEYNOTE-A39/EV-302) Trial of Padcev + Keytruda for Locally Advanced or Metastatic Urothelial Cancer (la/mUC)

Shots:

• Pfizer & Astellas have reported follow-up data from P-III (KEYNOTE-A39/EV-302) trial assessing Padcev + Keytruda vs Pt-based CT in previously untreated la/mUCpts (n=886)
• The 12mos. follow up study (mFU: 29.1mos.) showed reduced risk of death by 49% & decrease in PFS by 52% (mPFS: 12.5 vs 6.3mos.) with improved mOS (33.8 vs 15.9mos.), where OS benefit was observed in all prespecified groups (incl. cisplatin eligible & ineligible pts) 
• Additionally, an exploratory analysis in evaluable pts showed higher cORR (67.5% vs. 44.2%), with mDoR of 23.3 vs 7mos., plus cCR was achieved in 30.4% vs 14.5% pts, where median duration of cCR was not reached for enfortumab regimen vs 15.2mos. for CT; Data to be presented at ASCO GU

Ref: Businesswire | Image: Pfizer & Astellas

Related News:- Pfizer Reveals Data from P-III (BREAKWATER) trial of Braftovi Regimen in Patients with Metastatic Colorectal Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com